CCCCC4 Therapeutics, Inc.
Price
+26%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, growth steady, the market undecided.
Charts
As reported to the SEC, without any scoring.
C4 Therapeutics, Inc. (CCCC) reported revenue of $6.6M in Q2 2026 (quarter ended Jun 30, 2026), up 2.8% from the same quarter a year earlier. That came with net loss of $24M. For the full year FY2025, revenue was $36M (+1.0% year on year) and net income −$105M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 25, 2026On September 25, 2026, the Company announced new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma ( “RRMM”), as well as preliminary biomarker data from the first two patients in the ongoing Phase 1b trial of …Regulation FD disclosure · Form 8-K
- Aug 11, 2026C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
- Jun 11, 2026On June 11, 2026, the Company posted on its website a poster presentation with further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (“RRMM”), to be presented at the …Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.